Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Recurrence 1Ovarian Neoplasms 1Neuroblastoma 1Medulloblastoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 6sonidegib 4Irinotecan 3Topotecan 2LY2940680 2Cyclophosphamide 2ribociclib 1pomalidomide 1palbociclib 1omburtamab I-131 1exatecan 1entrectinib 1dinutuximab 1bempegaldesleukin 1abemaciclib 1TB-403 1Pemetrexed 1ONC206 1Nivolumab 1NVP-LEQ506 1Granulocyte-Macrophage Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Etoposide 1CLR1404 1Biological Factors 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Medulloblastoma × TB-403 × Clear all
NCT02748135 2021-01-13

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Oncurious NV

Phase 1 Completed
18 enrolled
CNSSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡